Because the prevalence of CP-CRE is greater inhospitals and LTCFs compared to the community,17 laboratories may be prioritizing resources for carbapenemase testing to caresettings at highest risk for CP-CRE and to the patients with more severe infections.Furthermore, high-complexity VAMCs located in urban areas and affiliated withacademic centers were more likely to perform carbapenemase testing and to test fornon-KPC carbapenemases. The gene discussed is CP; the disease is infection.